(Q57632337)

10

object named as

Ludwig Kappos

0 references

Enrico Girardi

7

object named as

Enrico Girardi

0 references

author name string

Carolina Scagnolari

1

0 references

Petra Duda

2

0 references

Francesca Bagnato

3

0 references

Gabriella Vito

4

0 references

Alessia Alberelli

5

0 references

Vito Lavolpe

6

0 references

Valentina Durastanti

8

0 references

Guido Antonelli

https://scigraph.springernature.com/pub.10.1007/s00415-006-0332-7

11

0 references

publication date

10 April 2007

0 references

published in

Journal of Neurology

0 references

volume

254

0 references

issue

5

0 references

page(s)

597-604

0 references

exact match

0 references

cites work

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-006-0332-7

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-006-0332-7

Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-006-0332-7

Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-006-0332-7

Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-006-0332-7

Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-006-0332-7

Genomic effects of IFN-beta in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-006-0332-7

A one-year study on the pharmacodynamic profile of interferon-beta1a in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-006-0332-7

Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results

21 January 2018

1 reference

12 December 2020

Quantitation of neutralization of interferon by antibody

1 reference

12 December 2020

Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon

1 reference

12 December 2020

The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems

1 reference

12 December 2020

Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo

1 reference

12 December 2020

Development of interferon-beta as a therapy for multiple sclerosis

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

No evidence for genetic linkage between development of multiple sclerosis and components of the IFN system and the JAK-STAT pathway

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

1 reference

12 December 2020

Interferons and interferon inhibitory activity in disease and therapy.

1 reference

12 December 2020

Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b

1 reference

12 December 2020

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

1 reference

12 December 2020

Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice?

1 reference

12 December 2020

Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1.

1 reference

12 December 2020

Serum levels of soluble interferon Alfa/Beta receptor as an inhibitory factor of interferon in the patients with chronic hepatitis C

1 reference

12 December 2020

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

12 December 2020

Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR.

1 reference

12 December 2020

Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.

1 reference

12 December 2020

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

12 December 2020

The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.

1 reference

12 December 2020

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

A comparative study of the relative bioavailability of different interferon beta preparations

1 reference

12 December 2020

Mechanism(S) of interferon inhibitory activity in blood from patients with AIDS and patients with lupus erythematosus with vasculitis

1 reference

12 December 2020

Epitope specificity of neutralizing antibodies against IFN-beta

1 reference

12 December 2020

Increased levels of antiviral MxA protein in peripheral blood of patients with a chronic disease of unknown etiology

1 reference

12 December 2020

Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a

1 reference

12 December 2020

Regulation of interferon receptor expression in human blood lymphocytes in vitro and during interferon therapy

1 reference

12 December 2020

Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis

1 reference

12 December 2020

Interferon-β antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies

1 reference

12 December 2020

Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection.

1 reference

12 December 2020

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

1 reference

12 December 2020

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

12 December 2020

High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG.

1 reference

12 December 2020

SOCS-1 and SOCS-3 inhibit IFN-alpha-induced expression of the antiviral proteins 2,5-OAS and MxA.

1 reference

12 December 2020

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

1 reference

12 December 2020

Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b

1 reference

12 December 2020

Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study

1 reference

12 December 2020

Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials

1 reference

12 December 2020

Neutralizing and binding antibodies to IFN-beta: relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-beta preparations

1 reference

12 December 2020

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.

1 reference

12 December 2020